|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Preclinical Experimental Therapeutics |
Brain Tumor Center and Departments of Neurosurgery (A.B.H., E.W., V.K.H., T.S., Z.C., J.G., R.S., F.F.L.), Biostatistics (K.R.H.), and Neuro-Oncology (C.A.C.), The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030; Hilton Head Regional Medical Center, Hilton Head, SC 29926 (E.C.M.); USA
2 Address correspondence to Amy B. Heimberger, Department of Neurosurgery, The University of Texas M.D. Anderson Cancer Center, Unit 442, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA (aheimber{at}mdanderson.org).
Abstract
Rapamycin has previously been shown to be efficacious against intracerebral
glioma xenografts and to act in a cytostatic manner against gliomas. However,
very little is known about the mechanism of action of rapamycin. The purpose
of our study was to further investigate the in vitro and in vivo mechanisms of
action of rapamycin, to elucidate molecular end points that may be applicable
for investigation in a clinical trial, and to examine potential mechanisms of
treatment failure. In the phosphatase and tensin homolog deleted from
chromosome 10 (PTEN)-null glioma cell lines U-87 and D-54, but not the
oligodendroglioma cell line HOG (PTEN null), doses of rapamycin at the
IC50 resulted in accumulation of cells in G1, with a
corresponding decrease in the fraction of cells traversing the S phase as
early as 24 h after dosing. All glioma cell lines tested had markedly
diminished production of vascular endothelial growth factor (VEGF) when
cultured with rapamycin, even at doses below the IC50. After 48 h
of exposure to rapamycin, the glioma cell lines (but not HOG cells) showed
downregulation of the membrane type-1 matrix metalloproteinase (MMP) invasion
molecule. In U-87 cells, MMP-2 was downregulated, and in D-54 cells, both
MMP-2 and MMP-9 were downregulated after treatment with rapamycin. Treatment
of established subcutaneous U-87 xenografts in vivo resulted in marked tumor
regression (P < 0.05). Immunohistochemical studies of subcutaneous
U-87 tumors demonstrated diminished production of VEGF in mice treated with
rapamycin. Gelatin zymography showed marked reduction of MMP-2 in the mice
with subcutaneous U-87 xenografts that were treated with rapamycin as compared
with controls treated with phosphatebuffered saline. In contrast, treatment of
established intracerebral U-87 xenografts did not result in increased median
survival despite inhibition of the Akt pathway within the tumors. Also, in
contrast with our findings for subcutaneous tumors, immunohistochemistry and
quantitative Western blot analysis results for intracerebral U-87 xenografts
indicated that there is not significant VEGF production, which suggests
possible deferential regulation of the hypoxia-inducible factor 1
in
the intracerebral compartment. These findings demonstrate that the complex
operational mechanisms of rapamy-cin against gliomas include cytostasis,
anti-VEGF, and anti-invasion activity, but these are dependent on the in vivo
location of the tumor and have implications for the design of a clinical
trial.
References
Blouw, B., Song, H., Tihan, T., Bosze, J., Ferrara, N., Gerber, H.P., Johnson, R.S., and Bergers, G. (2003) The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4,133 -146.[CrossRef][ISI][Medline]
Brugarolas, J.B., Vazquez, F., Reddy, A., Sellers, W.R., and Kaelin, W.G., Jr. (2003) TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4, 147-158.[CrossRef][ISI][Medline]
Dilling, M.B., Dias, P., Shapiro, D.N., Germain, G.S., Johnson,
R.K., and Houghton, P.J. (1994) Rapamycin selectively inhibits
the growth of childhood rhabdomyosarcoma cells through inhibition of signaling
via the type I insulin-like growth factor receptor. Cancer
Res. 54,903
-907.
El-Hashemite, N., Walker, V., Zhang, H., and Kwiatkowski, D.J.
(2003) Loss of Tsc1 or Tsc2 induces vascular endothelial growth
factor production through mammalian target of rapamycin. Cancer
Res. 63,5173
-5177.
Eshleman, J.S., Carlson, B.L., Mladek, A.C., Kastner, B.D., Shide,
K.L., and Sarkaria, J.N. (2002) Inhibition of the mammalian
target of rapamycin sensitizes U87 xenografts to fractionated radiation
therapy. Cancer Res. 62,7291
-7297.
Fang, J., Yan, L., Shing, Y., and Moses, M.A. (2001)
HIF-1alpha-mediated up-regulation of vascular endothelial growth factor,
independent of basic fibroblast growth factor, is important in the switch to
the angiogenic phenotype during early tumorigenesis. Cancer
Res. 61,5731
-5735.
Guba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., Hornung, M., Bruns, C.J., Zuelke, C., Farkas, S., Anthuber, M., Jauch, K.W., and Geissler, E.K. (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat. Med. 8, 128-135.[CrossRef][ISI][Medline]
Houchens, D.P., Ovejera, A.A., Riblet, S.M., and Slagel, D.E. (1983) Human brain tumor xenografts in nude mice as a chemotherapy model. Eur. J. Cancer Clin. Oncol. 19,799 -805.[CrossRef][ISI][Medline]
Hudson, C.C., Liu, M., Chiang, G.G., Otterness, D.M., Loomis, D.C.,
Kaper, F., Giaccia, A.J., and Abraham, R.T. (2002) Regulation of
hypoxia-inducible factor 1alpha expression and function by the mammalian
target of rapamycin. Mol. Cell Biol.
22,7004
-7014.
Lal, S., Lacroix, M., Tofilon, P., Fuller, G.N., Sawaya, R., and Lang, F.F. (2000) An implantable guide-screw system for brain tumor studies in small animals. J. Neurosurg. 92,326 -333.[ISI][Medline]
Lang, F.F., Gilbert, M.R., Puduvalli, V.K., Weinberg, J., Levin, V.A., Yung, W.K., Sawaya, R., Fuller, G.N., and Conrad, C.A. (2002) Toward better early-phase brain tumor clinical trials: A reappraisal of current methods and proposals for future strategies. Neuro-Oncol. 4,268 -277.[Abstract]
Neshat, M.S., Mellinghoff, I.K., Tran, C., Stiles, B., Thomas, G.,
Petersen, R., Frost, P., Gibbons, J.J., Wu, H., and Sawyers, C.L.
(2001) Enhanced sensitivity of PTEN-deficient tumors to
inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA
98,10314
-10319.
Price, D.J., Grove, J.R., Calvo, V., Avruch, J., and Bierer, B.E.
(1992) Rapamycin-induced inhibition of the 70-kilodalton S6
protein kinase. Science
257,973
-977.
Rooprai, H.K., Rucklidge, G.J., Panou, C., and Pilkington, G.J. (2000) The effects of exogenous growth factors on matrix metalloproteinase secretion by human brain tumour cells. Br. J. Cancer 82,52 -55.[CrossRef][ISI][Medline]
Schuler, W., Sedrani, R., Cottens, S., Haberlin, B., Schulz, M., Schuurman, H.J., Zenke, G., Zerwes, H.G., and Schreier, M.H. (1997) SDZ RAD, a new rapamycin derivative: Pharmacological properties in vitro and in vivo. Transplantation 64, 36-42.[CrossRef][ISI][Medline]
Sehgal, S.N., Baker, H., and Vézina, C. (1975) Rapamycin (AY-22,989), a new antifungal antibiotic, II. Fermentation, isolation and characterization. J. Antibiot. (Tokyo) 28,727 -732.[Medline]
Supko, J.G., and Malspeis, L. (1994) Dose-dependent pharmacokinetics of rapamycin-28-N,N-dimethylglycinate in the mouse. Cancer Chemother. Pharmacol. 33,325 -330.[ISI][Medline]
Treins, C., Giorgetti-Peraldi, S., Murdaca, J., Semenza, G.L., and
Van Obberghen, E. (2002) Insulin stimulates hypoxia-inducible
factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent
signaling pathway. J. Biol. Chem.
277,27975
-27981.
Tsuzuki, Y., Fukumura, D., Oosthuyse, B., Koike, C., Carmeliet, P.,
and Jain, R.K. (2000) Vascular endothelial growth factor (VEGF)
modulation by targeting hypoxia-inducible factor-1alpha
hypoxia response
element VEGF cascade differentially regulates vascular response and
growth rate in tumors. Cancer Res.
60,6248
-6252.
Zhang, D., and Brodt, P. (2003) Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling. Oncogene 22,974 -982.[CrossRef][ISI][Medline]
This article has been cited by other articles:
|
|
 |
|
  L. Yang, M. J. Clarke, B. L. Carlson, A. C. Mladek, M. A. Schroeder, P. Decker, W. Wu, G. J. Kitange, P. T. Grogan, J. M. Goble, et al. PTEN Loss Does Not Predict for Response to RAD001 (Everolimus) in a Glioblastoma Orthotopic Xenograft Test Panel Clin. Cancer Res., June 15, 2008; 14(12): 3993 - 4001. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sliwa, D. Markovic, K. Gabrusiewicz, M. Synowitz, R. Glass, M. Zawadzka, A. Wesolowska, H. Kettenmann, and B. Kaminska The invasion promoting effect of microglia on glioblastoma cells is inhibited by cyclosporin A Brain, February 1, 2007; 130(2): 476 - 489. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
